Tag:

Salix Pharmaceuticals

Latest Headlines

Latest Headlines

Will Allergan bid for Salix as it looks to escape Valeant's clutches?

Allergan CEO David Pyott has hinted he might make a pickup to thwart Valeant's attempts to take over his company. And now that one-time target Shire is off the table after being snatched up by AbbVie, his sights may be set on Salix.

Could buying Salix get Valeant off of Allergan's scent?

Allergan, working to fend off a hostile approach from Valeant Pharmaceuticals, is reportedly taking a look at the smaller Salix Pharmaceuticals, weighing a multibillion-dollar deal that could render it unattainable--or at least drive up its asking price.

Salix wins FDA approval for a rare disease drug

Salix Pharmaceuticals picked up FDA approval for an orphan therapy, giving the company another revenue source as it plots a tax-saving move to Ireland.

Salix scores another FDA green light with approval for angioedema med Ruconest

In its second FDA nod this week, Salix Pharmaceuticals won the go-ahead for Ruconest, its first-in-class treatment for a rare genetic disease, hereditary angioedema.

Salix picks up Cosmo's Irish unit for $2.7B and a lower tax bill

Yet another U.S. company is orchestrating a deal that will allow it to move overseas and slash its tax rate. Salix Pharmaceuticals of North Carolina says it will merge with an Ireland-based unit of Cosmo Pharmaceutical and buy out some of its patents for drugs to treat gastrointestinal diseases for $2.7 billion in stock.

Should gastro specialist Salix snap up Furiex and its IBS drug candidate?

Should Salix Pharmaceuticals snap up its North Carolina neighbor Furiex Pharmaceuticals? The latter's bowel drug could slide right in to Salix's business, analysts said. And Furiex is scouting around for a potential buyer, Bloomberg reports.

Gastro specialist Salix nabs Santarus and new colitis drug in $2.6B deal

Salix Pharmaceuticals, the gastrointestinal drug specialist, has snapped up fellow specialty drugmaker Santarus in a $2.6 billion all-cash buyout.

Which drugs are the biggest duds in blockbuster-land?

EvaluatePharma researchers totted up sales for the last 5 years' worth of analysts' blockbuster picks--and found plenty of bad bets.

Last-minute drive at FDA added 6 new drug approvals

Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.

FDA approves 2nd botanical in 8 years, Fulyzaq from Salix

On the last day of the year, the FDA gave a thumbs up to the second botanical prescription drug it has ever approved, a full 6 years after the first was sanctioned. The recipient of this rare distinction was Fulyzaq, a drug marketed by Salix Pharmaceuticals for the treatment of diarrhea in HIV/AIDS patients who are on anti-retroviral therapy.